RayKnowChina Research Map
Shortlist

Not yet recruitingCoronary heart diseaseN/A

Registered title, quoted from ClinicalTrials.gov

OPTIMized Diagnosis and Treatment System Based on AI and Multimodal Imaging Fusion for PCI (OPTIMAI-PCI)

An open trial on coronary heart disease, registered on ClinicalTrials.gov. Led by Zhejiang Hospital; 6 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Checklist for this trial 2

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (2 points)Hide the checklist
  1. 18 years to 80 years; sex: all

    Registered eligibility fields

  2. Pregnant or breastfeeding participant, or plans for pregnancy or breastfeeding during the study.

    Exclusion criterion 8

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; stage or severity, as the trial defines it; earlier treatment; day-to-day activity level; blood tests: counts, liver and kidney function; scans and measurable lesions; other conditions the trial excludes.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07855614, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Age 18 to 80 years, inclusive, at the time of informed consent.
  • Planned PCI for a target non-left-main coronary lesion meeting at least one of the following: typical myocardial ischemic symptoms with angiographic stenosis >70%; atypical symptoms with angiographic stenosis >=90%; functional measurement by FFR or QFR <0.80; or minimum lumen area below the protocol threshold for vessel diameter (<2.4 mm2 for <3.0 mm, <2.7 mm2 for 3.0-3.5 mm, or <3.6 mm2 for >3.5 mm).
  • Complex coronary lesion: a single diffuse long lesion >20 mm or tandem lesions separated by >10 mm of non-diseased vessel.
  • Participant or legally authorized representative can understand and sign written informed consent, can follow study procedures, and agrees to required contraception during the study.

Exclusion Criteria:

  • Allergy or contraindication to heparin, aspirin, P2Y12 receptor antagonists, or contrast media, except contrast allergy controllable by premedication.
  • Active pathologic bleeding or gastrointestinal or genitourinary bleeding within 3 months before PCI.
  • Bleeding tendency or known coagulation disorder, including heparin-induced thrombocytopenia.
  • Life expectancy <1 year or inability to comply with the protocol, in the investigator's judgment.
  • Bypass graft lesion, left-main or unprotected left-main coronary lesion.
  • STEMI within 24 hours of symptom onset or cardiogenic shock at admission (Killip class IV).
  • Uncontrolled severe systemic disease, including severe hepatic, renal, hematologic, or psychiatric disease; examples include ALT or AST >3 times the upper limit of normal, total bilirubin >1.5 times the upper limit of normal, albumin <35 g/L, cirrhosis or uncontrolled ascites, eGFR <30 mL/min/1.73 m2 or dialysis, platelet count <50 x 10\^9/L, hemoglobin <80 g/L, hemolytic anemia, or aplastic anemia.
  • Pregnant or breastfeeding participant, or plans for pregnancy or breastfeeding during the study.
  • Target-vessel PCI within 12 months or in-stent restenosis.
  • Severe calcified lesion or major epicardial coronary ostial lesion expected to require atherectomy pretreatment.
  • IVUS catheter cannot cross the lesion.
  • Angiographic image quality inadequate for muQFR analysis, including severe overlap, insufficient projections, or poor contrast filling.

Withdrawal and Exclusion from Per-Protocol Analysis:

  • PCI not performed after randomization or key imaging missing and not recoverable; participant remains in the intention-to-treat set where applicable.
  • Withdrawal of informed consent.
  • Investigator judges continued participation may endanger the participant, such as a serious adverse event or very poor compliance.

Recruitment:

Participants will be screened among inpatients and outpatients scheduled for PCI for complex coronary lesions at participating centers. Investigators will explain the study and obtain written informed consent before enrollment.

Quoted from ClinicalTrials.gov, NCT07855614, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07855614, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07855614